We previously described an enhancer variant of Moloney murine leukaemia virus (M-MuLV), AMo + SV M-MuLV, in which the enhancers of MuLV have been deleted and replaced with the enhancers of the simian virus 40 (SV40). When this virus is injected into neonatal NIH Swiss mice, pre-B and B-lymphoblastic lymphomas develop with a latency of 17 months. Van Lohuizen et al. (1989) described a line of transgenic mice that carry an activated pim-1 proto-oncogene transgene (EB pim-1). They also reported that Ep pim-1 transgenic mice show greatly accelerated lymphoma development when infected with wild-type M-MuLV at birth. In these experiments, neonatal E~t pim-1 transgenic mice were infected intraperitoneally with AMo+SV M-MuLV. Marked acceleration of T-lymphoid leukaemia was seen. However, l0 of the 11 tumours analysed were found to be negative for the SV40 enhancers, but they still contained M-MuLV DNA as measured by Southern blot analysis. The LTRs on viruses cloned from two such tumours (as well as on virus recovered by infection onto NIH 3T3 cells) were characterized by PCR amplification, molecular cloning and sequence analysis. The LTR's from the two tumours were identical to each other and were distinct from both the AMo + SV MMuLV and wild-type M-MuLV LTRs. However, they were identical to a rearranged solo M-MuLV LTR present in the E~tpim-1 transgene. These results indicate that the recombination in vivo between AMo + SV MMuLV and the Eg pim-1 transgene yielded a replicationcompetent and pathogenic virus at high efficiency. This is the first report of in vivo recombination between an exogenous MuLV and a solo endogenous LTR.
Introduction
Moloney murine leukaemia virus (M-MuLV) is a replication-competent retrovirus that lacks an oncogene. Like most non-acute transforming retroviruses, MMuLV causes disease (T lymphoma) with a significant latency. A hallmark of carcinogenesis by non-acute transforming retroviruses is insertional activation of cellular proto-oncogenes Fan, 1990; Hayward et al., 1981; Selten et al., 1984) . In addition, MuLVs induce other events during leukaemogenesis, including events before outgrowth of the tumour cells (Fan, 1990) as well as events involved in tumour progression (Bear et al., 1989; Patriotis et al., 1993) .
Several investigators have shown that the disease specificity for different M-MuLV strains is governed by the tissue specificity of the viral enhancer sequences (Chatis et aI., 1983; DesGroseillers et al., 1983; Vogt et al., 1985) . This reflects the requirement of an active LTR * Author for correspondence. Fax +1 714 824 4023. e-mail HYFAN@UCI.edu for insertional activation of proto-oncogenes in the target cell for tumorigenesis. The MuLV enhancers may also affect other steps in the leukaemogenic process as well. We have generated a number of variants of MMuLV driven by chimeric LTRs with heterologous enhancer sequences (Brightman et al., 1991 (Brightman et al., , 1993 Davis et al., 1985; Feuer & Fan, 1990; Fan et al., 1986; Hanecak et al., 1986 Hanecak et al., , 1988 Hanecak et al., , 1991 Kitado & Fan, 1989; Overhauser & Fan, 1985) . Several of these viruses show altered pathogenic potentials, and they have been useful in analysing steps in the leukaemogenic process.
We previously described an M-MuLV enhancer variant, AMo+SV M-MuLV, in which the M-MuLV enhancers were replaced by enhancer sequences (the 75 bp and 21 bp repeats) from simian virus 40 (SV40) (Hanecak et al., 1988) . This virus was found to induce B lymphornas in newborn NIH Swiss mice with a very long latency-17 months for 50 % mortality.
The proto-oncogene pim-1 was originally isolated as a common integration site in M-MuLV-induced tumours. Pim-1 encodes a serine/threonine kinase similar to many previously isolated oncogenes (Racker, 1989) , but initially there was no conclusive evidence that pim-1 had oncogenic potential. Eg pim-1 transgenic mice were developed by van Lohuizen et al. (1989) . These mice carry a pim-1 transgene with a duplicated immunoglobulin heavy chain gene enhancer upstream of the pim-1 promoter and a single M-MuLV LTR within the 3'-untranslated region. Eta pim-1 mice that are heterozygous for the transgene formed spontaneous T lymphomas in only 5 to 10 % of uninoculated mice by 7 months. However, when these mice were injected at birth with M-MuLV they developed T cell lymphoblastic lymphoma with a mean latency of 7 to 8 weeks, as compared to 22 weeks in the parental strain C57BL/6 (van Lohuizen et al., 1989) . Given the long latency of disease associated with the AMo+SV MMuLV variant, as well as its induction of B lymphoma, it was interesting to infect this virus into Eg pim-1 mice to test for acceleration of disease. The results of such experiments are described here.
Methods
Viruses, cells and animals. The wild-type M-MuLV and AMo + SV M-MuLV used in these experiments were previously described (Hanecak et al., 1988) . Procedures for growth and titration of viruses were also described previously (Hanecak et al., 1988) . Heterozygous Eg pim-1 mice were obtained by crossing homozygous Ela pim-1 males (generously provided by Anton Berns) with C57BL/6 females. Ela pim-1 mice were inoculated intraperitoneally with approximately 105 XC p.f.u, of virus per animal within 48 h of birth. Moribund animals were sacrificed, gross pathology was noted and tissue sections were fixed in B5 fixative for histopathology.
Analysis of tumour DNAs. High molecular weight DNA was extracted from tumour tissues as described previously (Hanecak et al., 1988) . Tamour DNAs were digested with the appropriate restriction enzymes, and analysed by gel electrophoresis and Southern blot hybridization (Southern, 1975) with specific probes. The probes were random primer-labelled restriction fragments. A 0.18 kb M-MuLV LTR-specific XbaI-SmaI fragment from nucleotide -150 to + 30 was used as a probe. Probes for the following sequences were used as described previously (Hanecak et al., 1988) : the T cell receptor fl (TCR~) gene, the immunoglobulin la heavy chain (IgH) gene, the immunoglobulin kappa light chain [IgL(~c)] gene, SV40 sequences and M-MuLV env sequences (Bosselman et al., 1982) .
Infectious-centre assays of haematopoietic tissues and isolation of inJectious virus. These assays were carried out as described previously . Briefly, isolated single cell suspensions from the spleen, thymus and bone marrow of AMo+SV M-MuLV-infected mice were co-cultivated for 24 h with NIH 3T3 cultures (5 x 104 NIH 3T3 per 10cm dish) at concentrations ranging from 102 to 106 haematopoietic cells, in Dulbecco's modified Eagle's medium containing 10 % calf serum and 1 5 lag ofpolybrene per ml. After this time, the haematopoietic cells were removed by washing twice with PBS. After the NIH 3T3 cells reached confluence, they were either scored for foci of M-MuLV infection by the UV-XC assay (Rowe et al., 1970) , or the cells were passaged in the presence of 2 gg/ml of polybrene and assayed by UV-XC overlay until they were confluently infected. DNA was then isolated from the confluently infected cells as described previously (Hanecak et al., 1988) .
PCR cloning of M-MuLV LTRs from tumours. Forward and reverse oligonucleotides complementary to M-MuLV and spanning the ClaI site in env and the SacI site in the LTR at positions 7674 and 8229 (5'-ATTCTTAATCGATTAGTCCA-3' and 5'-TTTATTGAGCTCGG-GGAGC-Y, respectively) were synthesized for PCR. Of each primer 50 pmol was used in a 100 lal volume containing 0.2 gM of nucleotide tripbosphates and 2-5 U Taq polymerase (Perkin-Elmer Cetus) and 1 gg of turnout cell DNA. After denaturation at 94 °C for 5 min, samples were incubated for 35 cycles in a thermal cycler (94 °C for 30 seconds, 50 °C for 30 seconds, and 72 °C for 1 min per cycle). Amplified fragments were digested with ClaI plus SaeI, and cloned into similarly digested pBluescript SKII. These clones were then sequenced by the didexoynucleotide chain termination method using a Pharmacia automated laser fluorescent (ALF) sequencer and sequencing kit, which included fluorescently labelled universal primers. A fluorescently labelled oligonucleotide complementary to the U3 region position 7861 of the MuLV LTR (5'-CCATTTTGCAAGGCATG-3') was used for sequencing.
Results

Leukaemogenicity of AMo + SV M-MuL V in El2 pim-1 transgenic mice
Heterozygous E~ pim-1 transgenic mice were injected with AMo + SV M-MuLV within 48 h of birth, to test if there was cooperation between the activated pim-1 transgene and the weakly leukaemogenic AMo + SV MMuLV. The mice were then monitored for signs of disease and sacrificed when they appeared moribund. Leukaemic tissues were also saved for histopathology and molecular analysis. The time course of disease is shown in Fig. 1 . As reported previously, the latency of B lymphoma was 17 months in AMo+SV M-MuLVinfected NIH Swiss mice (Hanecak et al., 1988) . However, 50 % ofAMo + SV M-MuLV-infected Egpim-1 transgenic mice developed lymphoma in 6 months, a marked acceleration. In contrast only 6 % of heterozygous uninfected Eta pim-1 transgenic mice developed T cell lymphoblastic lymphoma within 7 months. Furthermore, no C57BL/6 mice (the genetic background for transgenics) infected with AMo+SV M-MuLV developed disease by 9 months. Therefore, AMo-SV MMuLV infection was responsible for accelerated leukaemogenicity in Ela pim-1 transgenic mice.
Characterization of tumours #z Ekt pim-1 transgenic mice infected with AMo+ SV M-MuLV
It was important to determine the type of leukaemia occurring in the AMo + SV M-MuLV-infected transgenic mice, since AMo + SV M-MuLV-infected mice develop B lymphoma, whereas Ela pim-1 transgenic mice spontaneously develop T lymphoma (van Lohuizen et al., 1989) , and wild-type M-MuLV infection of these mice leads to high incidence of T lymphoma. To determine the tumour types, tumours from leukaemic mice were characterized by gross pathology, histopathology and molecular analysis for T cell TCRp and immunuglobulin la heavy chain (IgH) and kappa light chain (Ig~c) gene 1~ Data for AMo + SV M-MuLV-induced tumours in NIH Swiss mice was previously reported (Hanecak et al., 1988) . § LL, Lymphoblastic Lymphoma; FCC lymphoma, Folicular Centre Cell lymphoma; AML, Acute Mylogenous Leukemia.
M -M u L V leukaemogenesis in transgenic mice
Diagnosis of tumours from AMo + S V M -M u L V-inoculated and uninoculated Ect pim-1 transgenic mice
II Represents results of Southern blot analysis as follows: R, rearranged; G, germ line; G/R, primarily germ line configuration but showing a subpopulation of cells in the tumour carrying rearranged loci. ND, not done.
r e a r r a n g e m e n t s o n S o u t h e r n b l o t s as d e s c r i b e d prev i o u s l y ( H a n e c a k et al., 1988) .
L y m p h o b l a s t i c l y m p h o m a s
s h o w n to h a v e T C R p r e a r r a n g e m e n t s ( w i t h o r w i t h o u t t h e I g H g e n e r e a r r a n g e m e n t s ) w e r e classified as T l y m p h o i d , w h e r e a s t h o s e w i t h n o T C R~ g e n e r e a r r a n g e m e n t s b u t r e a r r a n g e m e n t s o f I g H ( w i t h o r w i t h o u t Ig~c r e a r r a n g e m e n t s ) w e r e classified as B or pre-B. B origin were detected in AMo + SV M-MuLV-infected NIH Swiss mice, along with B cell derived follicular centre cell lymphoma. In addition, three mice showed acute myelogenous leukaemia (AML) with or without B lymphoma. Two mice also showed T cell lymphoma, but SV40 sequences were not present in these tumours, suggesting that either the tumours were of non-viral origin, or that they were induced by variant viruses that had lost the SV40 sequences.
W e r e p o r t e d p r e v i o u s l y t h a t
When tumours from heterozygous Ep pim-1 transgenic mice neonatally infected with AMo + SV M-MuLV were analysed, 11 out of 11 were classified as T lymphoid by the molecular analyses as also shown in Table 1 . Consistent with this, gross pathology of these mice showed extensive tumour involvement in the thymus as evidenced by greatly enlarged thymuses. Spleen and lymph nodes of these mice were also usually enlarged. The one control uninoculated heterozygous Eg pim-1 transgenic mouse that was analysed was also found to have a T lymphoid tumour.
Presence of virus in tumours
To assure that the acceleration of disease in the transgenic mice was indeed due to viral infection, high molecular weight DNAs from thymic or splenic tumours of moribund animals were tested by Southern blot hybridization for the presence of AMo + SV M-MuLV provirus using an SV40 enhancer-specific probe as described previously (Hanecak et al., 1988) . SmaI digestion will liberate an internal 2.09 kb fragment that hybridizes with an SV40 enhancer-specific DNA probe. In addition, although Sinai is a methylation-sensitive restriction enzyme that will not cut well in the methylated mouse genomic DNA (since it contains the dinucleotide CpG in its recognition site), some viral host-junction fragments would also be expected (Fig. 2 a) . As illustrated in Fig. 2 b) none of the 11 tumours contained AMo + SV M-MuLV proviral DNA that could be detected by the SV40 enhancer sequence probe. This unexpected result raised the possibility that the tumours arising in the transgenic mice did not contain virus sequences. Alternatively, the tumours might have been infected with a variant of M-MuLV that did not contain SV40 sequences. To test this possibility, the blot of Fig. 2b was stripped and re-hybridized with an M-MuLV env gene probe (Fig. 2 c) . Ten of the 11 tumours analysed yielded the diagnostic M-MuLV fragment when hybridized with the envelope gene probe, indicating that they were MMuLV infected, but that a variant virus was present in the tumours. Presumably, some form of rearrangement had occurred in the infected transgenic mice giving rise to the tumorigenic viruses. The data also indicated that the rearrangements involved the enhancer sequences in the LTR, with loss of the SV40 sequences. When tumour cells from two of these mice were co-cultivated with NIH 3T3 fibroblasts, infectious XC-positive viruses were recovered. They showed the same hybridization patterns with both the SV40 enhancer-specific, and M-MuLV env probes as shown in Fig. 2(b and c) lane 10. The one tumour that was also M-MuLV-negative by the env probe probably did not harbour virus; the animal may have died of a spontaneous T lymphoma characteristic of uninfected Eg pim-1 transgenic mice (van Lohuizen et al., 1989) .
One possible explanation for the high frequency of LTR rearrangements observed in the tumours was that AMo + SV M-MuLVs may have been unable to replicate in C57BL/6 mice (the background strain for the transgenics); this could exert strong selective pressure for any rearrangements that improve replication. However, AMo + SV M-MuLV-infected C57BL/6 mice that were sacrificed at 16 weeks of age and analysed for the presence of virus showed detectable virus with the SV40 enhancer-containing probe (lane 11 of Fig. 2 b) . On the other hand, these mice harboured very low levels of infectious virus as measured by infectious centre assay (data not shown).
Cloning the var&nt LTRs
In order to determine the exact sequence of the rearrangements that had occurred in the LTR in the tumours, M-MuLV-specific LTR sequences were cloned out of the tumours of two mice using PCR. In addition, to ensure that the cloned LTRs were reflective of replication-competent virus, LTR sequences were also PCR cloned from virus recovered from one of the tumours by infection onto NIH 3T3 fibroblasts. In order to avoid cloning out any endogenous retroviral sequences, two oligonucleotide primers were used that had previously been employed to preferentially clone MMuLV LTRs from virus-induced tumours in NIH Swiss mice (Brightman et al., 1993) . Positive clones were characterized with respect to insert size, and representative clones with the predicted sized inserts were sequenced. The sequence of the LTRs cloned from both tumours and also from infectious virus from one tumour were identical, and they contained new sequences not present in the AMo + SV M-MuLV LTR, as shown in Fig. 3(a) . Moreover, the SV40 sequences were absent. This was consistent with the Southern blot analysis of Fig. 2(b and c) .
The identity of the LTRs from two independently arising tumours was striking, and suggested a common mechanism for generation of the rearrangement. Furthermore, analysis of these clones indicated that they resembled a rearranged wild-type M-MuLV LTR, as shown in Fig. 3(b) . In particular, the new sequences present in the rearranged LTRs from the tumours could be found in the enhancer sequences of the wild-type MMuLV LTR. The clones all contained a characteristic rearrangement relative to the wild-type M-MuLV LTR in which there was a deletion between base pairs 8008 and 8028 and an insertion at this site of a duplication of base pairs 8083 to 8161 and then a 6 bp non-M-MuLV sequence (GAAACA) (Fig. 4) . Furthermore, from one of the tumours a second smaller clone was isolated that contained a deletion between base pairs 7946 and 8028 and an insertion of only the 6 bp sequence GAAACA (Fig. 4) . When DNA from this tumour was digested with SmaI and probed with the MuLV env gene probe, two bands were seen, consistent with this tumour containing viruses with two different LTRs (Fig. 2c, lane 7) . The most likely explanation for this was that LTR #2 arose from LTR # 1 by deletion of the duplicated sequences as well as the sequences between 7946 and 8008.
Initially, the appearance of wild-type M-MuLVrelated enhancer sequences in the rearranged LTR was puzzling, since AMo+SV M-MuLV completely lacks these sequences. One possible source could be the MMuLV LTR present in the pim-1 transgene. The organization of the pim-1 transgene is shown in Fig. 5 .
The transgene contains a solo M-MuLV LTR derived from previously cloned integrated M-MuLV proviruses as described in the figure legend. The absence of any other M-MuLV sequences in the transgene was confirmed by direct sequencing of the transgene plasmid prior to generation of the transgenic animals (M. van Lohuizen & A. Berns, personal communication). Dr Anton Berns provided us with the sequence of the MMuLV LTR present in the transgene of Eg pim-1 mice (Berns et aL, 1983) , which had previously been found to contain a rearrangement (Berns et al., 1983) . The sequence of the transgene LTR was identical to the sequences contained within the rearranged LTRs in the tumours, as shown in Fig. 3 (c) . These results strongly suggested that the transgene was the source of the new LTRs present in the tumours, and that recombination between the transgene LTR and AMo + SV M-MuLV had occurred in vivo, giving rise to a tumorigenic MMuLV variant.
Discussion
In these experiments we describe the acceleration of T lymphoid leukaemia when neonatal Ela pim-1 transgenic mice were inoculated with AMo + SV M-MuLV. Egpim-1 mice infected with AMo+SV M-MuLV developed disease with a mean latency of 6 months. In contrast only 6 % of uninfected heterozygous Ep.pim-1 mice developed T lymphoma within 7 months.
Furthermore, no C57BL/6 mice (the genetic background for the transgenics) infected with AMo + SV MMuLV developed disease by 10 months. When tumours were analysed they were found to contain proviruses with variant LTRs lacking SV40 sequences. The sequence data of Fig. 3 BamHI-KpnI fragment from a clone of a proviral insertion from a tumor . Recombination between retroviral genomes during mixed infections with genetically marked viruses is well documented in the avian (Blair et al., 1976; Wyke & Beamand, 1979) , murine (Wong & McCarter, 1973; Faller& Hopkins, 1978) , and human (Clavel et al., 1989) viral systems. In addition, exogenous retroviruses can also recombine with endogenous retroviral sequences (Bosselman et al., 1982) . The mink cell focus-inducing (MCF) recombinants of MuLVs result from recombination in vivo between ecotropic MuLVs and endogenous polytropic retroviral sequences; MCF recombinants play an important role(s) in tumour formation. Recombination between integrated retroviral DNA sequences and infecting retrovirus has also been described in vitro (Olson et al., 1992) . However, this is the first documented case where in vivo recombination between an exogenous retrovirus and an endogenous ' solo LTR' (an LTR surrounded by non-viral sequences) has been shown. As shown in Fig. 5 , the only viral sequences present in the pim-1 transgene are the LTR sequences. In other cases where LTR recombination between an exogenous and endogenous retrovirus occurs (e.g. generation of pathogenic MCF MuLV recombinants in AKR mice) the endogenous LTR is part of a complete endogenous provirus (Stoye et al., 1991) . This allows for efficient co-packaging of an endogenous viral RNA with exogenous viral RNA for recombination (see below).
The recombination between AMo + SV M-MuLV and the transgene LTR could have occurred either during reverse transcription, or, potentially by DNA:DNA homologous recombination. The prevailing view is that retroviral recombination occurs via copy-choice reverse transcription from RNAs packaged into heterozygous virus particles (Stuhlmann & Berg, 1992; Coffin, 1979) , and that co-packaging of the RNAs participating in recombination is required for the process (Hu & Temin, 1990) . Packaging of RNA into virions is most efficient when viral cis packaging signals are present (e.g. the q~ site) (Linial et al., 1978) . The putative packaging of transgene RNA (that contains the rearranged LTR in the 3' end) into virus particles to allow for recombination involving the LTR was therefore somewhat unexpected. However, packaging of cellular RNAs that lack retroviral packaging signals into retroviral virions has also been demonstrated (Aronoff & Linial, 1991) . It also has been shown that transgene expression is high in both B lymphoid and T lymphoid cells as well as in many other organs in these transgenic mice (van Lohuizen et al., 1989) . Thus, significant transgene RNA packaging into virions is plausible. In addition, the presence of the MMuLV LTR in the T-untranslated region of the pim-1 RNA transcript might also enhance packaging of this transcript, although the LTR does not contain the classical q~ sequences.
We cannot rule out the possibility that the recombination occurred through DNA:DNA homologous recombination. It has been suggested that rearrangements in retroviral LTRs (that do not encode viral protein) occur by DNA recombination or gene conversion (Olson et al., 1992; Goodrich & Duesberg, 1990a, b) .
These tumours were also tested for traditional MCF recombinants by Southern blot hybridization as described previously. However, no MCF recombinants were detected, even at the level of one MCF provirus per tumour cell (data not shown). This was interesting, because during infection with wild-type M-MuLV, MCF recombinants are almost always detected, beginning soon after infection (Evans, 1986) . Moreover, recombinant MuLVs isolated from these tumours closely resembled wild-type M-MuLV. We have also shown that AMo+SV M-MuLV can form MCF recombinants in vivo, although apparently at relatively late times (E. L. Suchman, R. C. Hanecak, P. K. Pattengale & H. Fan, unpublished results). Thus, high frequency of MCF formation might have been expected. However, the endogenous retroviruses that contribute the env sequences to MCF recombinants are probably not expressed at the high levels of the pim-1 transgene, so less opportunity for recombination with these sequences might have existed. This still does not explain the lack of MCF formation, once the pseudo-wild-type M-MuLV had been generated. Perhaps the lack of detectable MCF provirus formation might be related to the timing. MCF recombinants have generally been detected in mice that have been infected by MuLVs (exogenous or endogenous) at or near birth. We have shown that initial levels of AMo+SV M-MuLV viraemia in neonatally infected animals are relatively low, so the pseudo-wild-type MMuLV generated in the infected transgenic mice might have arisen at relatively late times, after which formation of MCF recombinants might have been less efficient, or at which MCFs did not enhance tumour formation.
These results suggest that this system may serve as an interesting model for the study of retroviral recombination in vivo. Furthermore, the results show that other MuLV infections in EIa pim-1 mice might result in the appearance of equivalent recombinants. This may be important for interpretation of further leukaemogenesis studies in these mice.
